Alnylam Pharmaceuticals (ALNY) Expected to Announce Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is anticipated to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of $1.63 per share and revenue of $1.3241 billion for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the business earned ($0.44) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 96.4% compared to the same quarter last year. On average, analysts expect Alnylam Pharmaceuticals to post $7 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $278.40 on Tuesday. Alnylam Pharmaceuticals has a 52 week low of $262.21 and a 52 week high of $495.55. The stock has a market capitalization of $37.17 billion, a P/E ratio of 76.07 and a beta of 0.27. The firm has a fifty day simple moving average of $292.06 and a two-hundred day simple moving average of $315.16. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94.

Insider Activity

In other news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Orbis Allan Gray Ltd lifted its stake in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 23.6% during the fourth quarter. AQR Capital Management LLC now owns 919,959 shares of the biopharmaceutical company’s stock valued at $365,822,000 after buying an additional 175,951 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Northern Trust Corp now owns 857,742 shares of the biopharmaceutical company’s stock worth $341,081,000 after buying an additional 24,591 shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $369,943,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 4.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 647,839 shares of the biopharmaceutical company’s stock worth $257,613,000 after acquiring an additional 29,069 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on ALNY. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Royal Bank Of Canada reduced their price objective on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. Citigroup began coverage on Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price objective on the stock. Finally, Morgan Stanley raised their price objective on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the company an “equal weight” rating in a research note on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $452.13.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.